Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (211-220 of 471) with videos related to

Pageof 48
Sort By:
European Heart Journal|July 19, 2013
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trialTimothy J Collier, Stuart J Pocock, John J V McMurray, et al.
Circulation|October 9, 2012
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizationsJennifer K Rogers, John J V McMurray, Stuart J Pocock, et al.
Journal of the American College of Cardiology|December 19, 2012
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trialJaved Butler, Haris Subacius, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|June 27, 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trialLuca Monzo, Nicolas Girerd, Kevin Duarte, et al.
Circulation. Heart Failure|June 15, 2021
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF TrialJoão Pedro Ferreira, Zohra Lamiral, John J V McMurray, et al.
European Journal of Heart Failure|January 11, 2020
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunctionPatrick Rossignol, Kevin Duarte, Nicolas Girerd, et al.
European Journal of Heart Failure|September 12, 2018
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trialNadia Bouabdallaoui, Brian Claggett, Michael R Zile, et al.
Journal of the American College of Cardiology|May 12, 2012
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) programDavide Castagno, Hicham Skali, Madoka Takeuchi, et al.
European Journal of Heart Failure|July 17, 2013
Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trialSaeed Payvar, John A Spertus, Alan B Miller, et al.
European Journal of Heart Failure|May 30, 2002
Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failureMonica R Shah, Vic Hasselblad, Sandra S Stinnett, et al.
Pageof 48

Showing results (211-220 of 471) with videos related to

Sort By:
Pageof 48
European Heart Journal|July 19, 2013
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trialTimothy J Collier, Stuart J Pocock, John J V McMurray, et al.
Circulation|October 9, 2012
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizationsJennifer K Rogers, John J V McMurray, Stuart J Pocock, et al.
Journal of the American College of Cardiology|December 19, 2012
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trialJaved Butler, Haris Subacius, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|June 27, 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trialLuca Monzo, Nicolas Girerd, Kevin Duarte, et al.
Circulation. Heart Failure|June 15, 2021
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF TrialJoão Pedro Ferreira, Zohra Lamiral, John J V McMurray, et al.
European Journal of Heart Failure|January 11, 2020
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunctionPatrick Rossignol, Kevin Duarte, Nicolas Girerd, et al.
European Journal of Heart Failure|September 12, 2018
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trialNadia Bouabdallaoui, Brian Claggett, Michael R Zile, et al.
Journal of the American College of Cardiology|May 12, 2012
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) programDavide Castagno, Hicham Skali, Madoka Takeuchi, et al.
European Journal of Heart Failure|July 17, 2013
Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trialSaeed Payvar, John A Spertus, Alan B Miller, et al.
European Journal of Heart Failure|May 30, 2002
Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failureMonica R Shah, Vic Hasselblad, Sandra S Stinnett, et al.
Pageof 48